🏛️ Verified NIH Record • Updated 2026-01-13
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia (NCT06429449)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: University of Colorado, Denver
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Hospital — Aurora, Colorado
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Colorado Hospital — Aurora, Colorado
📞 Contact the Study Coordinator
Phone: (720) 848-0628
Email: derek.schatz@cuanschutz.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Leukemia
- Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia — San Diego, California
- AZD6738 for Patients With Progressive MDS or CMML — Boston, Massachusetts
- Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies — Philadelphia, Pennsylvania
- Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 — New York, New York
- Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL — Chicago, Illinois
- Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors — Memphis, Tennessee
Explore by condition: All Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.